167 related articles for article (PubMed ID: 28465589)
1. Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.
Carriero MV; Bifulco K; Ingangi V; Costantini S; Botti G; Ragone C; Minopoli M; Motti ML; Rea D; Scognamiglio G; Botti G; Arra C; Ciliberto G; Pessi A
Sci Rep; 2017 May; 7(1):1312. PubMed ID: 28465589
[TBL] [Abstract][Full Text] [Related]
2. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Ragone C; Minopoli M; Ingangi V; Botti G; Fratangelo F; Pessi A; Stoppelli MP; Ascierto PA; Ciliberto G; Motti ML; Carriero MV
J Exp Clin Cancer Res; 2017 Dec; 36(1):180. PubMed ID: 29216889
[TBL] [Abstract][Full Text] [Related]
3. The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.
Ingangi V; Bifulco K; Yousif AM; Ragone C; Motti ML; Rea D; Minopoli M; Botti G; Scognamiglio G; Fazioli F; Gallo M; De Chiara A; Arra C; Grieco P; Carriero MV
Oncotarget; 2016 Aug; 7(34):54474-54487. PubMed ID: 27323409
[TBL] [Abstract][Full Text] [Related]
4. Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity.
Minopoli M; Polo A; Ragone C; Ingangi V; Ciliberto G; Pessi A; Sarno S; Budillon A; Costantini S; Carriero MV
Sci Rep; 2019 Aug; 9(1):12169. PubMed ID: 31434916
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.
Minopoli M; Botti G; Gigantino V; Ragone C; Sarno S; Motti ML; Scognamiglio G; Greggi S; Scaffa C; Roca MS; Stoppelli MP; Ciliberto G; Losito NS; Carriero MV
J Exp Clin Cancer Res; 2019 Nov; 38(1):459. PubMed ID: 31703596
[TBL] [Abstract][Full Text] [Related]
6. A urokinase receptor-derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting.
Bifulco K; Longanesi-Cattani I; Liguori E; Arra C; Rea D; Masucci MT; De Rosa M; Pavone V; Stoppelli MP; Carriero MV
Mol Cancer Ther; 2013 Oct; 12(10):1981-93. PubMed ID: 23939376
[TBL] [Abstract][Full Text] [Related]
7. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis.
Prevete N; Liotti F; Visciano C; Marone G; Melillo RM; de Paulis A
Oncogene; 2015 Jul; 34(29):3826-38. PubMed ID: 25263443
[TBL] [Abstract][Full Text] [Related]
8. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.
Bifulco K; Longanesi-Cattani I; Franco P; Pavone V; Mugione P; Di Carluccio G; Masucci MT; Arra C; Pirozzi G; Stoppelli MP; Carriero MV
PLoS One; 2012; 7(9):e44806. PubMed ID: 23049759
[TBL] [Abstract][Full Text] [Related]
9. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
10. Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration.
Yousif AM; Ingangi V; Merlino F; Brancaccio D; Minopoli M; Bellavita R; Novellino E; Carriero MV; Carotenuto A; Grieco P
Eur J Med Chem; 2018 Jan; 143():348-360. PubMed ID: 29202399
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
Gupta R; Chetty C; Bhoopathi P; Lakka S; Mohanam S; Rao JS; Dinh DE
Int J Oncol; 2011 Mar; 38(3):733-44. PubMed ID: 21181094
[TBL] [Abstract][Full Text] [Related]
12. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
Tummalapalli P; Gondi CS; Dinh DH; Gujrati M; Rao JS
Int J Oncol; 2007 Jul; 31(1):5-17. PubMed ID: 17549400
[TBL] [Abstract][Full Text] [Related]
13. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas.
Gondi CS; Lakka SS; Yanamandra N; Olivero WC; Dinh DH; Gujrati M; Tung CH; Weissleder R; Rao JS
Cancer Res; 2004 Jun; 64(12):4069-77. PubMed ID: 15205313
[TBL] [Abstract][Full Text] [Related]
15. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.
Kargiotis O; Chetty C; Gogineni V; Gondi CS; Pulukuri SM; Kyritsis AP; Gujrati M; Klopfenstein JD; Dinh DH; Rao JS
Int J Oncol; 2008 Nov; 33(5):937-47. PubMed ID: 18949356
[TBL] [Abstract][Full Text] [Related]
16. Subpopulations of uPAR+ contribute to vasculogenic mimicry and metastasis in large cell lung cancer.
Li Y; Sun B; Zhao X; Zhang D; Wang X; Zhu D; Yang Z; Qiu Z; Ban X
Exp Mol Pathol; 2015 Apr; 98(2):136-44. PubMed ID: 25661888
[TBL] [Abstract][Full Text] [Related]
17. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
18. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells.
Gorantla B; Asuthkar S; Rao JS; Patel J; Gondi CS
Mol Cancer Res; 2011 Apr; 9(4):377-89. PubMed ID: 21389187
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
Carriero MV; Longanesi-Cattani I; Bifulco K; Maglio O; Lista L; Barbieri A; Votta G; Masucci MT; Arra C; Franco R; De Rosa M; Stoppelli MP; Pavone V
Mol Cancer Ther; 2009 Sep; 8(9):2708-17. PubMed ID: 19706734
[TBL] [Abstract][Full Text] [Related]
20. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
